These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23954381)

  • 1. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.
    Abzug MJ; Song LY; Levin MJ; Nachman SA; Borkowsky W; Pelton SI;
    Vaccine; 2013 Oct; 31(42):4782-90. PubMed ID: 23954381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Chang SY; Chang SC
    Hum Vaccin Immunother; 2013 Feb; 9(2):398-404. PubMed ID: 23291936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults.
    Rossheim AE; Young AM; Siik J; Cunningham TD; Troy SB
    Hum Vaccin Immunother; 2016 Aug; 12(8):2117-2123. PubMed ID: 27172241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.
    Madhi SA; Izu A; Violari A; Cotton MF; Panchia R; Dobbels E; Sewraj P; van Niekerk N; Jean-Philippe P; Adrian PV;
    Vaccine; 2013 Jan; 31(5):777-83. PubMed ID: 23228814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial.
    Pomat WS; van den Biggelaar AH; Phuanukoonnon S; Francis J; Jacoby P; Siba PM; Alpers MP; Reeder JC; Holt PG; Richmond PC; Lehmann D;
    PLoS One; 2013; 8(2):e56698. PubMed ID: 23451070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
    Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
    Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine.
    Rose MA; Schubert R; Strnad N; Zielen S
    Clin Diagn Lab Immunol; 2005 Oct; 12(10):1216-22. PubMed ID: 16210486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
    Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
    Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.
    Thisyakorn U; Chokephaibulkit K; Kosalaraksa P; Benjaponpitak S; Pancharoen C; Chuenkitmongkol S
    Hum Vaccin Immunother; 2014; 10(7):1859-65. PubMed ID: 25424793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants.
    Jones SA; Groome M; Koen A; Van Niekerk N; Sewraj P; Kuwanda L; Izu A; Adrian PV; Madhi SA
    PLoS One; 2013; 8(8):e72794. PubMed ID: 24015277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.
    King JC; Vink PE; Farley JJ; Parks M; Smilie M; Madore D; Lichenstein R; Malinoski F
    Pediatr Infect Dis J; 1996 Mar; 15(3):192-6. PubMed ID: 8852905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.
    Crum-Cianflone NF; Huppler Hullsiek K; Roediger M; Ganesan A; Patel S; Landrum ML; Weintrob A; Agan BK; Medina S; Rahkola J; Hale BR; Janoff EN;
    J Infect Dis; 2010 Oct; 202(7):1114-25. PubMed ID: 20795819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
    Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
    Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
    Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
    Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection.
    Bamford A; Kelleher P; Lyall H; Haston M; Zancolli M; Goldblatt D; Kampmann B
    AIDS; 2014 Sep; 28(14):2033-43. PubMed ID: 25222526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
    Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
    Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
    Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
    Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.